| CAS NO: | 25451-15-4 |
| 包装 | 价格(元) |
| 10mg | 电议 |
| 25mg | 电议 |
| Cas No. | 25451-15-4 |
| 别名 | 非尔氨酯; W-554; ADD-03055 |
| 化学名 | (3-carbamoyloxy-2-phenylpropyl) carbamate |
| Canonical SMILES | C1=CC=C(C=C1)C(COC(=O)N)COC(=O)N |
| 分子式 | C11H14N2O4 |
| 分子量 | 238.24 |
| 溶解度 | ≥ 11.9mg/mL in DMSO |
| 储存条件 | Store at -20°C |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
| 产品描述 | Felbamate (W-554) is a potent nonsedative anticonvulsant whose clinical effect may be related to the inhibition of N-methyl-D-aspartate (NMDA). Felbamate (W-554) is an anti-epileptic drug used in the treatment of epilepsy. It is used to treat partial seizures (with and without generalization) in adults and partial and generalized seizures associated with Lennox-Gastaut syndrome in children. However, an increased risk of potentially fatal aplastic anemia and/or liver failure limit the drugs usage to severe refractory epilepsy[1]. Felbamate (W-554) has been proposed to a unique dual mechanism of action as a positive modulator of GABAA receptors and as a blocker of NMDA receptors, particularly isoforms containing the NR2B subunit. Although it is clear that felbamate does cause pharmacological inhibition of NMDA receptor of relevance of NMDA receptor blockade as a strategy for the treatment of human epilepsy has been questioned. Therefore, the importance of the effects of felbamate on NMDA receptors to its therapeutic action in epilepsy is uncertain[2]. References: |
m.cnreagent.com